The company's market capitalisation of almost $2.5 billion, around ten times higher than three years ago, was driven by the commercialisation of its Australian-developed product for Rett syndrome.
Neuren reports growing US sales of Australian developed product for Rett syndrome
May 10, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 12, 2025 - - Latest News -
Rare Cancers Australia says election is the chance to end the ‘cancer lottery’
February 12, 2025 - - Latest News -
Specialised Therapeutics announces Thai approval of breast cancer therapy
February 12, 2025 - - Latest News -
Merck adds experienced industry executive to leadership team
February 11, 2025 - - Latest News -
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - - Latest News -
AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News -
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 - - Latest News